Andrew Bellinger, CSO & CMO at Verve Therapeutics, Inc. (VERV), sold 120,000 shares at $36.03 ($4.2M) on 2022-09-23, disclosed to the SEC on 2022-09-27.
Open-market sale of $4.2M VERV by CSO & CMO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $34.67 | 6,632 | $230K | 5.4% |
| 2 | $34.67 | 6,632 | $230K | 5.4% |
| 3 | $35.31 | 36,798 | $1.3M | 30.6% |
| 4 | $35.31 | 36,798 | $1.3M | 30.6% |
| 5 | $35.59 | 13,368 | $476K | 11.2% |
| 6 | $35.59 | 13,368 |
| $476K |
| 11.2% |
| 7 | $36.03 | 3,202 | $115K | 2.7% |
| 8 | $36.03 | 3,202 | $115K | 2.7% |
| Total | $35.34 avg | 120,000 | $4.2M | 100% |
| Filing → |
| VERV | SELL | 2022-07-22 | $698K | — | Filing → |
| VERV | SELL | 2022-07-15 | $249K | — | Filing → |
| VERV | SELL | 2021-12-27 | $1.2M | — | Filing → |